Cargando…

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas

Background: Diffuse gliomas are the most common malignant brain tumors, and immune checkpoint inhibitors have limited therapeutic effects against this cancer. Three oncogenic pathways are altered in diffuse gliomas: the RTK/Ras/PI3K/AKT signaling, TP53, and RB pathways. Although these pathways may a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Song, Wang, Peng-Fei, Cai, Hong-Qing, Wan, Jing-Hai, Li, Shou-Wei, Lin, Ze-Huan, Yu, Chun-Jiang, Yan, Chang-Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221357/ https://www.ncbi.nlm.nih.gov/pubmed/34100771 http://dx.doi.org/10.18632/aging.203102

Ejemplares similares

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
por: Colardo, Mayra, et al.
Publicado: (2021)

Tumorigenicity of RTK/RAS in urothelium
por: Wu, Xue-Ru, et al.
Publicado: (2015)

RTK-RAS pathway mutation is enriched in myeloid sarcoma
por: Choi, Mihong, et al.
Publicado: (2018)

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
por: Carrot-Zhang, Jian, et al.
Publicado: (2021)

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
por: Carrot-Zhang, Jian, et al.
Publicado: (2021)

Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2018)

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
por: Haddadi, Nahal, et al.
Publicado: (2018)

K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis
por: Liu, Lihui, et al.
Publicado: (2008)

Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets
por: Pudewell, Silke, et al.
Publicado: (2021)

Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine
por: Schwark, Kallen, et al.
Publicado: (2022)

Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature
por: Wojtas, Bartosz, et al.
Publicado: (2019)

A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma
por: Read, Renee D., et al.
Publicado: (2009)

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
por: Unni, Arun M, et al.
Publicado: (2018)

Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma
por: Yin, Xiang-Qian, et al.
Publicado: (2022)

Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
por: Song, Kyung W., et al.
Publicado: (2022)

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
por: Akutagawa, Jon, et al.
Publicado: (2016)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

The inhibition of Bax activation-induced apoptosis by RasGRP2 via R-Ras-PI3K-Akt signaling pathway in the endothelial cells
por: Takino, Jun-ichi, et al.
Publicado: (2019)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors
por: Pladevall-Morera, David, et al.
Publicado: (2022)

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells()
por: Wu, Y. Linda, et al.
Publicado: (2017)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

Chuanxiong improves angiogenesis via the PI3K/AKT/Ras/MAPK pathway based on network pharmacology and DESI-MSI metabolomics
por: Cheng, Xue-hao, et al.
Publicado: (2023)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2016)

Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells
por: Strittmatter, Brady G., et al.
Publicado: (2021)

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
por: Wang, Fei, et al.
Publicado: (2022)

Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells
por: Tahir, Analhuda Abdullah, et al.
Publicado: (2015)

Targeting RTK Signaling Pathways in Cancer
por: Regad, Tarik
Publicado: (2015)

The trigger (and the restriction) of Torso RTK activation
por: Mineo, Alessandro, et al.
Publicado: (2018)

On the Problem of Double-Filtering in PPP-RTK
por: Khodabandeh, A., et al.
Publicado: (2022)

PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma
por: Pfeifer, Matthias, et al.
Publicado: (2013)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

RNF7 promotes glioma growth via the PI3K/AKT signalling axis
por: Tang, Nan, et al.
Publicado: (2022)

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
por: Taylor-Harding, Barbie, et al.
Publicado: (2014)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

The Importance of Being PI3K in the RAS Signaling Network
por: Cuesta, Cristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6uslitnmms5uuh7d2gfo94v24